The FDA has approved the expansion of two dosing regimens (once a week and twice a week) including the combined use of dexamethasone (DKd) for the treatment of relapsed or refractory multiple myeloma (R/R-MM) Patients with 1-3 courses of treatment. In the combined treatment of refractory myeloma with these two drugs, their respective research results have shown the effectiveness of this drug.
Multiple myeloma is a blood cancer characterized by remission and recurrence. The prognosis of patients with each relapse will worsen. With the increasing use of first-line immunomodulatory drug therapies, the number of patients treated with these drugs may increase over time. This has created a need for effective treatment options for recurrence. "Despite continuous progress in the treatment of multiple myeloma, this disease is still incurable, and it is especially challenging for patients who have relapsed or are difficult to cure with existing treatments. "," said the clinical research director of hematological malignancies and a doctor of medicine for plasma cell diseases; a professor of clinical medicine, "as clinicians, choosing this program means that we can now combine two effective targeted drugs in a new immunomodulatory system. In drug-free triple therapy, this program has proven to have a deep and long-lasting response to relapsed patients."
Betadex sulfobutyl ether sodium(SBE-β-CD) is a derivative of β-CD, which has a negatively charged side chain and has a special effect on positively charged drugs. Hydrophobic drugs are After inclusion, the water solubility of the drug itself can be improved, and the absorption of the drug in the human body can also be increased, and the stability can be improved. In addition, it can form a non-covalent complex with drug molecules well, thereby improving drug safety, reducing nephrotoxicity, alleviating drug hemolysis, controlling drug release rate, and masking unpleasant odors. SBE-β-CD has been applied to injection medicine, oral medicine, nasal medicine, eye medicine, and has special affinity and inclusion properties for nitrogen-containing drugs.